

HPTN 083–01 – Safety, Tolerability and Acceptability of Long-Acting Cabotegravir for the Prevention of HIV among Adolescent Males – A sub-study of HPTN 083
Atlas Open Report – May 13, 2024
Visit Cutoff Date: May 13, 2024
Table O4 – Visit Completion ¹ by Visit and Site

	Overall	Boston	Chicago – AYAR	Aurora	Memphis
Total Participants Enrolled	9	4	3	1	1
Step 1					
Week 2	9/9 (100.0%)	4/4 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 4	9/9 (100.0%)	4/4 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Step 2					
Participants entering Step 2 ²	9/9 (100.0%)	4/4 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 6 Safety Visit	9/9 (100.0%)	4/4 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 9 (Injection # 2)	9/9 (100.0%)	4/4 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 10 Safety Visit	8/9 (88.9%)	3/4 (75.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 17 (Injection # 3)	8/8 (100.0%)	3/3 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 18 Safety Visit	8/8 (100.0%)	3/3 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 25 (Injection # 4)	8/8 (100.0%)	3/3 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 26 Safety Visit	8/8 (100.0%)	3/3 (100.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 33 (Injection # 5)	7/8 (87.5%)	2/3 (66.7%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week 34 Safety Visit	7/8 (87.5%)	2/3 (66.7%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Step 3 Oral TDF/FTC					
Week +8	3/3 (100.0%)	1/1 (100.0%)	2/2 (100.0%)	0/0 (-%)	0/0 (-%)
Week +12	2/3 (66.7%)	0/1 (0.0%)	2/2 (100.0%)	0/0 (-%)	0/0 (-%)
Week +24	2/3 (66.7%)	1/1 (100.0%)	1/2 (50.0%)	0/0 (-%)	0/0 (-%)
Week +36	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)
Week +48	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)	0/0 (-%)	0/0 (-%)
Step 3 Injection CAB LA					
Week +8	4/5 (80.0%)	1/2 (50.0%)	1/1 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week +16	4/5 (80.0%)	1/2 (50.0%)	1/1 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week +24	5/5 (100.0%)	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week +32 ³	6/6 (100.0%)	2/2 (100.0%)	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week +40	6/6 (100.0%)	2/2 (100.0%)	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)
Week +48	6/6 (100.0%)	2/2 (100.0%)	2/2 (100.0%)	1/1 (100.0%)	1/1 (100.0%)

¹ Visit Completion at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator will exclude any participants who are terminated, HIV – infected or have permanently discontinued study product at the time of the visit – no participants meet this criteria right now.

² Week 5 marks the beginning of Step 2 visits. Only participants who have attended their 5 visits in step 2 are included in step 3 section of the table, therefore visit completion rate is 100%.

³ One participant switched from Step3 Oral TDF/FTC to Step3 Injection CAB LA

HPTN 083–01 – Safety, Tolerability and Acceptability of Long–Acting Cabotegravir for the Prevention of HIV among Adolescent Males – A sub–study of HPTN 083
Atlas Open Report – May 13, 2024
Visit Cutoff Date: May 13, 2024
Table O5 – Retention by Site at Six–Month Intervals

	Overall	Boston	Chicago – AYAR	Aurora	Memphis
Total Participants Enrolled	9	4	3	1	1
Month 6	8/9 (88.9%)	3/4 (75.0%)	3/3 (100.0%)	1/1 (100.0%)	1/1 (100.0%)